Kåre Schultz, Chairman and CEO of Teva, spoke today during the presentation of the results for the second quarter of 2022.
Responding to questions from attendees, Schultz said, “We are still planning to launch UZEDY, which is the brand name for long-acting injectable risperidone, in the first half of next year.”
He then went on to say that this “long-acting risperidone product looks extremely good from a clinical standpoint, both in terms of efficacy and safety”, and that “it will be a major improvement over long-acting injectable antipsychotics.” You can take it subcutaneously and the product works for a month or two. It’s going to be really good to get final approval and launch the product next year.”